



Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/038,270			
		Filing Date	January 4, 2002			
		First Named Inventor	SCHOONJANS			
		Group Art Unit	1632			
		Examiner Name	Theresa Frederick			
Sheet	2	of	2	Attorney Docket Number	4029-012233	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.			T ²	
PP	1	✓	E.D. Rosen et al., <i>Mice lacking factor VII develop normally but suffer fatal perinatal bleeding</i> ; Nature, Vol. 390, 1997; 290-293			
	2		M. Dewerchin et al., <i>Generation and Characterization of Urokinase Receptor-deficient Mice</i> ; J. Clin. Invest. © The American Society for Clinical Investigation, Inc., Vol. 97, No. 3, 1996; 870-878			
	3		L.A. Galli-Taliadoros et al., <i>Gene knock-out technology: a methodological overview for the interested novice</i> ; Journal of Immunological Methods 181, 1995; 1-15			
	4		M.E. Donohue et al., <i>Targeted Disruption of Mouse Yin Yang 1 Transcription Factor Results in Peri-Implantation Lethality</i> , Molecular and Cellular Biology, Oct. 1999, 7237-7244			
	5		S. O'Gorman et al., <i>Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian Cells</i> , Reports, March 15, 1999; 1351-1355			
	6		S. Fukushige et al., <i>Genomic targeting with a positive-selection lox integration vector allows highly reproducible gene expression in mammalian cells</i> , Proc. Natl. Acad. Sci. USA, Vol. 89, September 1992; 7905-7909			
	7		C.J. Yee et al., <i>Expression and Characterization of Biologically Active Human Hepatocyte Growth Factor (HGF) by Insect Cells Infected with HGF-Recombinant Baculovirus</i> , Biochemistry, 1993; 32, 7922-7931			
	8		K. Araki et al., <i>Targeted integration of DNA using mutant lox sites in embryonic stem cells</i> , Nucleic Acids Research, 1997, Vol. 25, No. 4; 868-872			
	9		E.B. Rucker, J.A. Piedrahita, <i>Cre-Mediated Recombination at the Murine Whey Acidic Protein (mWAP) Locus</i> , Molecular Reproduction and Development, 1997; 48:324-331			
	10		Y-Q Feng et al., <i>Site-specific Chromosomal Integration in Mammalian Cells: Highly Efficient CRE Recombinase-mediated Cassette Exchange</i> , J. Mol. Biol. (1999) 292, 779-785			
	11		J-L Liu et al., <i>Conditional Knockout of Mouse Insulin-Like Growth Factor-1 Gene Using the Cre/loxP System (44500)</i> , P.S.E.B.M., 2000; Vol 223:344-351			
	12		M. Kolot et al., <i>Site-specific recombination in mammalian cells expressing the Int recombinase of bacteriophage HK022</i> , Molecular Biology Reports 26: 207-213; 1999			
	13		B.E. Clausen et al., <i>Conditional gene targeting in macrophages and granulocytes using LysMcre mice</i> , Transgenic Research 8:265-277; 1999			
	PP	14		K. Rajewsky et al., <i>Perspective Series: Molecular Medicine in Genetically Engineered Animals</i> , J. Clin. Invest., Vol. 98, No. 3; August 1996; 600-603		
Examiner Signature	Pete Parviz			Date Considered	1/22/04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.

{W0031932.1}

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<div>Complete if Known</div> <div>Application Number 10/038,279</div> <div>Filing Date January 4, 2002</div> <div>First Named Inventor Luc SCHOONJANS</div> <div>Group Art Unit 1632</div> <div>Examiner Name Theresa Frederick</div> <div>Attorney Docket Number 4029-012233</div>	
<div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>					
Sheet	1	of	1		

[illegible][illegible]

Examiner Signature	<i>Pete Kurnaz</i>	Date Considered	<i>1/23/04</i>
-----------------------	--------------------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.

{W0020855.1}

RECEIVED

OCT 01 2002

TECH CENTER/800/2889



Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/038,270		
		Filing Date	January 4, 2002		
		First Named Inventor	SCHOONJANS		
		Group Art Unit	1632		
		Examiner Name	Theresa Frederick		
Sheet	2	of	2	Attorney Docket Number	4029-012233

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T ²
PP	3	BASHOR, Dispersion and Disruption of Tissues, journal, 1979, 119-131,	
PP	4	STROJEK ET AL., A method for cultivating morphologically undifferentiated embryonic stem cells from porcine blastocysts, journal, 1990, 901-913.	
PP	5	DU ET AL., Nuclear transfer of putative rabbit embryonic stem cells leads to normal blastocyst development, journal, 1995, 249-253. <i>OK document has been found</i>	
PP	6	GILES ET AL., Pluripotency of cultured rabbit inner cell mass cells detected by isozyme analysis and eye pigmentation of fetuses following injection into blastocysts or morulae, journal, 1993, 130-136.	
PP	7	GRAVES ET AL., Derivation and characterization of putative pluripotent embryonic stem cells from preimplantation rabbit embryos, journal, 1993, 424-434.	
PP	8	SCHOONJANS ET AL., Pluripotent rabbit embryonic stem (ES) cells are capable of forming overt coat color chimeras following injection into blastocysts, journal, 1996, 439-443.	

Examiner Signature	<i>Pete Parnas</i>	Date Considered	<i>1/22/04</i>
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED
OCT 01 2002
JECB CENTER 1609/2999